A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult
DOI:
https://doi.org/10.32677/ijcr.v8i3.3317Keywords:
Spondyloarthritis, Tumor necrosis factor-α inhibitor, Infliximab, AdalimumabAbstract
Therapeutic options for patients with Spondyloarthritis (SpA) are limited. The present-day pharmacotherapy for Spondyloarthritis comprises immunomodulator/suppressive drugs. In this case report, we describe a 29-year old Postgraduate resident in Medicine who was diagnosed with spondyloarthritis and was managed by a combination of various disease-modifying drugs like methotrexate and sulfasalazine and immunomodulators such as systemic corticosteroids as well as Tumor Necrosis Factor-alfa inhibitors. After a series of therapeutic trials with them, the chimeric TNF blocker Infliximab led to significant clinical improvement in symptoms and reduction in disease activity.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Dr. Kanishk Yadav; Dr. Sachin Kuchya, Dr. Akshata Kalyani
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.